Abstract

To assess whether polymorphisms of genes related to estrogen biosynthesis and metabolism are associated with EGFR mutations. We studied 617 patients with lung adenocarcinoma, including 302 never-smoking women. On the basis of multiple candidate genes approach, the effects of polymorphisms of CYP17, CYP19A1, ERα, and COMT in association with the occurrence of EGFR mutations were evaluated using logistic regression analysis. In female never-smokers, significant associations with EGFR L858R mutation were found for the tetranucleotide (TTTA)(n) repeats in CYP19A1 (odds ratio, 2.6; 95%CI, 1.2-5.7 for 1 or 2 alleles with (TTTA)(n) repeats >7 compared with both alleles with (TTTA)(n) repeats ≤ 7), and the rs2234693 in ERα (OR, 2.1; 95% CI, 1.1-4.0 for C/T and C/C genotypes compared with T/T genotype). The C/C genotype (vs. T/T genotype) of ERα was significantly associated with EGFR L858R mutation (OR, 3.0; 95% CI, 1.1-8.1), in-frame deletion (OR, 2.9; 95% CI, 1.1-7.6) and other mutations (OR, 4.3; 95% CI, 1.3-14.0). The genotype of COMT rs4680 was significantly associated with EGFR L858R mutation in female and male never-smokers showing OR's (95% CI) of 1.8 (1.0-3.2) and 3.6 (1.1-11.3), respectively, for genotypes G/A and G/G compared with genotype A/A. The number of risk alleles of CYP17, CYP19A1, ERα, and COMT was associated with an increasing OR of EGFR L858R mutation in female never-smokers (P = 0.0002 for trend). The L858R mutation of EGFR is associated with polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients.

Highlights

  • This study explored whether genetic polymorphisms of genes related to estrogen biosynthesis and metabolism are associated with epidermal growth factor receptor (EGFR) hotspot mutations

  • This study aimed to evaluate the associations between EGFR hotspot mutations in lung adenocarcinoma and genetic polymorphisms of CYP17, CYP19A1, ERa, and COMT

  • This study was approved by the Joint Institutional Review Board (JIRB) at 6 teaching hospitals and tertiary referral centers in Taiwan that participated in the Genetic Epidemiological Study of Lung Adenocarcinoma (GELAC) study and IRB of Taichung Veterans General Hospital, Taiwan

Read more

Summary

Introduction

Authors' Affiliations: 1Genomics Research Center; 2Institute of Biomedical Sciences, 3Taiwan Biobank, and 4Life Science Library, Academia Sinica; 5Graduate Institute of Epidemiology, College of Public Health, National Taiwan University; 6School of Medicine, National Yang-Ming University; 7Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine; 8Chest Department, Taipei Veterans General Hospital, Taipei; 9Division of Chest Medicine, Department of Internal Medicine, 10Department of Pediatrics and 11Division of Thoracic Surgery, Department of Surgery, Taichung Veterans General Hospital; 12Institute of Medical and Molecular Toxicology, Chung Shan Medical University; Institutes of 13Biomedical Sciences and 14Molecular Biology, National Chung-Hsing University; 15Cancer Center, China Medical University Hospital; 16School of Medicine; 17Graduate Institute of Environmental Science, China Medical University, Taichung; 18Department of Pulmonary and Critical Care, Chang Gung Memorial Hospital, Lincou; 19Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung; 20Department of Internal Medicine, National Cheng Kung University Hospital and College of Medicine, Tainan; and 21Division of Bios-. The efficacy of targeted therapies such as gefitinib or erlotinib to non–small cell lung cancer (NSCLC) patients tatistics and Bioinformatics, Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan. Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/). Yang contributed to this work and should be considered co-first authors

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call